ENDRA Life Sciences (NDRA) Stock Analysis & Winston Score

ENDRA Life Sciences is a small medical technology company developing a device called TAEUS, which stands for Thermo Acoustic Enhanced Ultrasound. This technology aims to detect liver fat (steatosis) using a modified ultrasound approach, without needing expensive MRI scans or invasive biopsies. The main customers would be hospitals, clinics, and doctors who screen patients for non-alcoholic fatty liver disease (NAFLD), a growing health problem worldwide. ENDRA is a pre-revenue company, meaning it has not yet generated meaningful product sales. It is based in Ann Arbor, Michigan, and operates primarily in the United States while pursuing regulatory clearances. The company is very small, with a micro-cap valuation, and funds operations mainly through equity offerings. Its potential advantage lies in offering a low-cost, point-of-care alternative to MRI for liver diagnostics, but the key risk is significant — ENDRA must secure regulatory approval, achieve commercialization, and raise sufficient capital to survive as a going concern.